← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER BETA-LACTAM ANTIBACTERIALS › Carbapenems
panipenem and betamipron
J01DH55
Forms & Strengths
- Powder for injection: 250 mg panipenem / 250 mg betamipron per vial
- Powder for injection: 500 mg panipenem / 500 mg betamipron per vial
Adult Dosing
- General infections: 0.5 g to 1 g of panipenem component daily divided into 2-3 doses, administered via IV infusion
- Severe infections: Up to 2 g daily divided into 2-4 IV infusions
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been firmly established; use generally avoided or restricted per institutional protocols
Indications
- Treatment of susceptible bacterial infections caused by gram-positive and gram-negative aerobes and anaerobes
- Complicated intra-abdominal infections
- Severe respiratory tract infections
- Complicated urinary tract infections
Mechanism of Action
- Panipenem is a carbapenem antibacterial that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs)
- Betamipron is a renal dehydropeptidase-I (DHP-I) inhibitor co-administered to prevent renal metabolism of panipenem and reduce renal accumulation/toxicity
Contraindications
- Hypersensitivity to panipenem, betamipron, or other carbapenem antibiotics
- History of severe hypersensitivity reactions to beta-lactams
- Epilepsy or history of seizures (due to risk of CNS toxicity)
Adverse Reactions
- Central nervous system effects including seizures, tremors, and headache, particularly in patients with underlying CNS disorders or renal impairment
- Hypersensitivity reactions including rash, urticaria, and anaphylaxis
- Gastrointestinal disturbances such as diarrhea, nausea, and vomiting
- Transient elevations in liver transaminases and BUN/creatinine
- Hematologic abnormalities including eosinophilia, leukopenia, and thrombocytopenia
Drug Interactions
- Valproic acid: Co-administration with carbapenems significantly decreases valproic acid serum concentrations, potentially leading to loss of seizure control
- Probenecid: May compete with renal excretion, potentially increasing plasma concentrations of panipenem/betamipron
Curated Content: Needs Vetting Before Put to Clinical Use